<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><rec-number>1019</rec-number><ref-type>Case Study </ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Curtis, Stephanie</style></author><author><style face="normal" font="default" size="100%">Dawson, Paul</style></author><author><style face="normal" font="default" size="100%">Moyer, James</style></author><author><style face="normal" font="default" size="100%">Zall, Robert</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Valley of Sorrow</style></title></titles><taxonomies><taxonomy><style  face="normal" font="default" size="100%">Trade Secrets</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Employer/Employee Relationships</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Science </style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Medicine</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Professional Responsibility</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Biology</style></taxonomy></taxonomies><pubtype><style  face="normal" font="default" size="100%">Case Study </style></pubtype><audience-level><style  face="normal" font="default" size="100%">ug</style></audience-level><dates><year><style  face="normal" font="default" size="100%">2004</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.bioethics.iastate.edu/classroom/valleysorrow.html</style></url></web-urls></urls><publisher><style face="normal" font="default" size="100%">Iowa State University, Office of Biotechnology </style></publisher><abstract><style face="normal" font="default" size="100%">Dr. Howard Johnson has been collaborating with a large pharmaceutical company who has been a large funder of his research.  He has been invited to be included in a discussion about the company's latest efforts to develop new compounds that could be used as antidotes to certain viral infections. Due to the nature of these compounds, they cannot be patented and the company is attempting to keep everything a secret so the process does not become available to their competitors. During the discussion, Dr. Johnson learns about the success of the compound in reducing the mortality of a certain type of fever by ninety percent.  The company plans to withhold distribution of the compound, due to the impossibility of making distribution of the compound profitable in developing countries.  However, if developed,  it would save tens of thousands of lives. </style></abstract></record></records></xml>